{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117681","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.920681+00:00","generated_at":"2026-06-21T20:01:28.112295+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Leap Therapeutics reports Q3 2022 net loss of $15.1M, up from $11.1M YoY","bullets":["Net loss $15.1M in Q3 2022 vs $11.1M in Q3 2021; R&D expenses $12.1M.","Cash and equivalents $78.3M at Sept 30, 2022; plus $1.3M R&D incentive receivable.","Enrolled first patient in Part C of DisTinGuish study (GEA) and DeFianCe study (CRC).","Presented updated DKN-01 clinical data at ESMO and SITC meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117681","json":"https://secwatch.observer/filing/0001104659-22-117681.json","markdown":"https://secwatch.observer/filing/0001104659-22-117681.md","text":"https://secwatch.observer/filing/0001104659-22-117681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/0001104659-22-117681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/tm2230251d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:01:28.112295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"251120e7e53f45b4cafcb7a9796896423d098b04","claim":"CYPHERPUNK TECHNOLOGIES INC. reported the third quarter ended September 30, 2022 results: net income $15.1 million.","evidence_excerpt":"Net Loss was $15.1 million for the third quarter 2022, compared to $11.1 million for the three months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/0001104659-22-117681-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$15.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}